H.R.3497 - MODDERN Cures Act of 2011

To promote the development of meaningful treatments for patients. view all titles (3)

All Bill Titles

  • Official: To promote the development of meaningful treatments for patients. as introduced.
  • Short: MODDERN Cures Act of 2011 as introduced.
  • Short: Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2011 as introduced.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.

Bill’s Views

  • Today: 4
  • Past Seven Days: 7
  • All-Time: 2,316
 
Introduced
 
House
Passes
 
Senate
Passes
 
President
Signs
 

 
11/18/11
 
 
 
 
 
 
 

Sponsor

Representative

Leonard Lance

R-NJ

View Co-Sponsors (48)

Official Summary

Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2011 or the MODDERN Cures Act of 2011 - Requires the Secretary of Health and Human Services (HHS) to: (1) establish the Advanced Diagnostics Education Council to recommend standard terms and definitions relate

Official Summary

Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2011 or the MODDERN Cures Act of 2011 - Requires the Secretary of Health and Human Services (HHS) to:
(1) establish the Advanced Diagnostics Education Council to recommend standard terms and definitions related to innovative diagnostics for use by patients, physicians, health care providers, payers, and policy makers.; and
(2) publish a guide regarding such terms and definitions. Sets forth additional factors for the Secretary to consider in determining the payment amount for new clinical diagnostic laboratory tests under gap filling procedures which are used when no comparable existing test is available. Extends the exclusivity period for a drug or biological product if the diagnostic test related to such drug has been determined by the Secretary to have been developed by, or with the participation of, the manufacturer or sponsor of the drug or biological product, and use of the diagnostic tests provides for or improves:
(1) the identification of a patient population for the drug or biological product; or
(2) the determination of the most appropriate treatment option for a patient population with the drug or biological product. Establishes a dormant therapy designation for drugs or biological products that address unmet medical needs. Gives such a drug or biological product 15 years of data exclusivity under which no drug can be approved by relying on the approval or licensure of the dormant therapy.

...Read the Rest


Latest Letters to Congress

See All Letters (2)
 


Vote on This Bill

100% Users Support Bill

1 in favor / 0 opposed
 

Send Your Rep a Letter

about this bill Support Oppose Tracking
Track with MyOC